Human IL-6 HS ELISA
- Regulatory Status
- RUO
- Incubation time
- 1 x 3 hr,1 x 30 min,1 x 15 min
- Kit size
- 12 x 8
- Specimen / Volumes
- 100 μL
- Standard range
- 1.56 - 50 pg/mL
- Substrate / isotope
- TMB 450 nm
Intended use
The Human IL-6 High Sensitivity ELISA kit is a solid phase sandwich ELISA for the in-vitro qualitative and quantitative determination of IL-6 in supernatants, buffered solutions or serum and plasma samples. This assay will recognise both natural and recombinant human IL-6.
Summary
Interleukin-6 (IL-6) is a multi-functional cytokine that regulates immune responses, acute phase reactions and hematopoiesis and may play a central role in host defense mechanisms (13, 31). The gene for human IL-6 has been localized to chromosome 7p21 (1). The genomic sequence has been determined (36). IL-6 is usually not produced constitutively by normal cells, but its expression is readily induced by a variety of cytokines (28), lipopolysaccharide (25) or viral infections (3). The IL-6 gene product is a single chain protein with a molecular mass ranging from 21 to 28 kDa, depending on the cellular source. Extensive posttranslational modifications like N- and O-linked glycosylation (20) as well as phosphorylation (21) seem to account for this heterogeneity. The cDNA for IL-6 predicts a precursor protein of 212 amino acids (10). IL-6 is a pleiotropic cytokine produced by a variety of cells. It acts on a wide range of tissues, exerting growth-induction, growth inhibition, and differentiation respectively, depending on the nature of the target cells. IL-6 is involved in:
- The induction of B-cell differentiation,
- The induction of acute phase proteins in liver cells,
- Growth promotion of myeloma/plasmacytoma/hybridoma cells,
- Induction of IL-2 and IL-2 receptor expression,
- Proliferation and differentiation of T cells,
- Inhibition of cell growth of certain myeloid leukemic cell lines and induction of their differentiation tomacrophages,
- Enhancement of IL-3-induced multipotential colony cell formation in hematopoietic stem cells andinduction of maturation of megakaryocytes as a thrombopoietic factor,
- Induction of mesangial cell growth,
- Induction of neural differentiation of PC 12 cells and
- Induction of keratinocyte growth (14).
The abnormal production of IL-6 was first suggested to be related to polyclonal B-cell activation with autoantibody production in patients with cardiac myxoma (9). Since then, IL-6 has been suggested to be involved in the pathogenesis of a variety of diseases. Measurement of IL-6 levels in serum and other body fluids thus provides more detailed insights into various pathological situations.
Infections:
Body fluids of patients with acute local bacterial or viral infections and serum of patients with gram-negative or positive bacteremia contain elevated levels of biologically active IL-6 (7, 16).
Obstetric Infections:
IL-6 has emerged as a reporter cytokine for intra-amniotic infection (29). Diseases associated with an altered immune system (polyclonal B-cell abnormalities or autoimmune diseases): Elevated levels of circulating IL-6 have been detected in patients with cardiac myxoma (11), Castleman's disease (18), rheumatoid arthritis (12), IgM gammopathy and in those with acquired immunodeficiency syndrome (19, 23) as well as alcoholic liver cirrhosis (2, 32).Proliferative diseases:
Elevated plasma levels of IL-6 are observed in patients with psoriasis (4, 5) and mesangial proliferative glomerulonephritis (15).
Neoplastic Diseases:
ncreased systemic levels of IL-6 have been detected in patients with multiple myeloma (22), other B-cell dyscrasias (27), Lennert's T lymphoma, Castleman's disease, renal cell carcinoma (33) and various other solid tumors (17, 30).
Inflammatory responses:
IL-6 is involved in the induction of acute phase proteins and induction of fever (8). Elevated serum levels of IL-6 are also found in patients with severe burns (24, 34), in serum and plasma as a marker for predicting postoperative complications (26), in serum and urine of recipients of kidney transplants before rejection (35), in the serum of septic shock patients (6) and in patients with inflammatory arthritis and traumatic arthritis.
This kit has been configured for research use only. Not suitable for use in therapeutic procedures.
- Bowcock AM and al. Genomics. 1988 Jul;3(1):8-16.
- Byl B. and al. Gastroenterology. 1993 May;104(5):1492-7.
- Cayphas S. and al. J Immunol. 1987 Nov 1;139(9):2965-9.
- Elder JT and al. Arch Dermatol Res. 1992;284(6):324-32.
- Grossman RM and al. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6367-71.
- Hack CE and al. Blood. 1989 Oct;74(5):1704-10.
- Helfgott DC and al. J Immunol. 1989 Feb 1;142(3):948-53.
- Helle M and al. Eur J Immunol. 1988 Jun;18(6):957-9.
- Hirano T and al. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5490-4.
- Hirano T and al. Nature. 1986 Nov 6-12;324(6092):73-6.
- Hirano T and al. Proc Natl Acad Sci U S A. 1987 Jan;84(1):228-31.
- Hirano T and al. Eur J Immunol. 1988 Nov;18(11):1797-801.
- Hirano T and al. Immunol Today. 1990 Dec;11(12):443-9.
- Horii Y and al. Kidney Int Suppl. 1993 Jan;39:S71-5.
- Houssiau FA and al. Clin Exp Immunol. 1988 Feb;71(2):320-3.
- Kishimoto T. Blood. 1989 Jul;74(1):1-10.
- Kishimoto T. And al. Annu Rev Immunol. 1988;6:485-512.
- Martínez-Maza O Res Immunol. 1992 Sep;143(7):764-9.
- May LT and al. J Biol Chem. 1988 Jun 5;263(16):7760-6.
- May LT and al. Biochem Biophys Res Commun. 1988 May 16;152(3):1144-50.
- Merico F and al. Clin Exp Immunol. 1993 Apr;92(1):27-31.
- Nakajima K and al. J Immunol. 1989 Jan15;142(2):531-6.
- Nijsten MW and al. Lancet. 1987 Oct 17;2(8564):921.
- Nordan R and al. Science. 1986 Aug 1;233(4763):566-9.
- Oka Y and al. Cytokine. 1992 Jul;4(4):298-304.
- Pettersson T and al. J Intern Med. 1992 Nov;232(5):439-42.
- Ray A and al. Ann N Y Acad Sci. 1989;557:353-61; discussion 361-2.
- Santhanam U and al. Cytokine. 1991 Mar;3(2):155-63.
- Seguchi T and al. J Urol. 1992 Sep;148(3):791-4.
- Sehgal PB and al. J Exp Med. 1988 Jun 1;167(6):1951-6.
- Sheron N and al. Clin Exp Immunol. 1991 Jun;84(3):449-53.
- Tsukamoto T and al. J Urol. 1992 Dec;148(6):1778-81; discussion 1781-2.
- Ueyama M and al. J Lab Clin Med. 1992 Nov;120(5):693-8.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.